NEUROCRINE BIOSCIENCES INC — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 29 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $806M | ↑+28.3% | $154M | ↑+49.1% | 26.2% |
| 2025-09-30 | $795M | ↑+27.8% | $210M | ↑+61.4% | 30.1% |
| 2025-06-30 | $688M | ↑+16.5% | $108M | ↑+65.4% | 21.2% |
| 2025-03-31 | $573M | ↑+11.1% | $8M | ↓-81.8% | 4.1% |
| 2024-12-31 | $628M | ↑+21.8% | $103M | ↓-30.2% | 22.6% |
| 2024-09-30 | $622M | ↑+24.7% | $130M | ↑+56.2% | 29.5% |
| 2024-06-30 | $590M | ↑+30.4% | $65M | ↓-31.9% | 24.6% |
| 2024-03-31 | $515M | ↑+22.6% | $43M | ↑+156.7% | 19.3% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$806M
↑+28.3% +$178M YoY
Net Income
$154M
↑+49.1% +$51M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
NBIX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyNBIX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics